HRP20050926A2 - Beta-carbolines useful for treating inflammatory disease - Google Patents

Beta-carbolines useful for treating inflammatory disease Download PDF

Info

Publication number
HRP20050926A2
HRP20050926A2 HR20050926A HRP20050926A HRP20050926A2 HR P20050926 A2 HRP20050926 A2 HR P20050926A2 HR 20050926 A HR20050926 A HR 20050926A HR P20050926 A HRP20050926 A HR P20050926A HR P20050926 A2 HRP20050926 A2 HR P20050926A2
Authority
HR
Croatia
Prior art keywords
hydrogen
aliphatic
halogen
amino
independently selected
Prior art date
Application number
HR20050926A
Other languages
English (en)
Croatian (hr)
Inventor
E. Hepperle Michael
D. Little Jeremy
Castro Alfredo
Mazdiyasni Hormoz
E. Fleming Paul
Reynolds Dominic
Fields Liu Julie
Soucy Frencois
Ye Yingchum
S. Murray Robert
Prakash Raman
Original Assignee
Millennium Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals filed Critical Millennium Pharmaceuticals
Publication of HRP20050926A2 publication Critical patent/HRP20050926A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HR20050926A 2003-04-09 2004-04-09 Beta-carbolines useful for treating inflammatory disease HRP20050926A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09
PCT/US2004/011080 WO2004092167A1 (fr) 2003-04-09 2004-04-09 Beta-carbolines utiles pour traiter une maladie inflammatoire

Publications (1)

Publication Number Publication Date
HRP20050926A2 true HRP20050926A2 (en) 2006-06-30

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050926A HRP20050926A2 (en) 2003-04-09 2004-04-09 Beta-carbolines useful for treating inflammatory disease

Country Status (22)

Country Link
US (2) US7727985B2 (fr)
EP (1) EP1611134A1 (fr)
JP (1) JP2006522824A (fr)
KR (1) KR20060006031A (fr)
CN (1) CN1802375A (fr)
AU (1) AU2004230952A1 (fr)
BR (1) BRPI0409263A (fr)
CA (1) CA2521300A1 (fr)
CO (1) CO5700746A2 (fr)
CR (1) CR8042A (fr)
EA (1) EA009121B1 (fr)
EC (1) ECSP056145A (fr)
HR (1) HRP20050926A2 (fr)
MA (1) MA27837A1 (fr)
MX (1) MXPA05010793A (fr)
NI (1) NI200500174A (fr)
NO (1) NO20054598L (fr)
OA (1) OA13115A (fr)
RS (1) RS20050832A (fr)
TN (1) TNSN05257A1 (fr)
WO (1) WO2004092167A1 (fr)
ZA (1) ZA200508198B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.
JP2007532582A (ja) * 2004-04-09 2007-11-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置に有用なβ−カルボリン
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
WO2007106884A2 (fr) * 2006-03-15 2007-09-20 Theralogics, Inc. Méthodes de traitement des maladies d'atrophie musculaire au moyen d'inhibiteurs de l'activation de nf-kb
WO2008002246A1 (fr) * 2006-06-28 2008-01-03 Astrazeneca Ab Composition pharmaceutique comprenant un inhibiteur de la ikk2 et un second ingrédient actif
US20100098641A1 (en) * 2006-12-13 2010-04-22 William Baker Monophosphates as Mutual Prodrugs of Anti-Inflammatory Signal Transduction Modulators (AISTM's) and Beta-Agonists for the Treatment of Pulmonary Inflammation and Bronchoconstriction
US20090131422A1 (en) * 2007-10-23 2009-05-21 Millennium Pharmaceuticals, Inc. Salts of an IKK inhibitor
WO2009054970A1 (fr) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Sel mésylate d'un inhibiteur d'ikk
JP5892791B2 (ja) 2008-05-14 2016-03-23 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 適応免疫における免疫調節物質の効果をモニターするための方法およびキット
PL2366699T3 (pl) 2008-10-02 2013-12-31 Asahi Kasei Pharma Corp 8-podstawiona pochodna izochinoliny i jej zastosowanie
US8748428B2 (en) 2010-03-30 2014-06-10 Novartis Ag Use of a PKC inhibitor
JP6049216B2 (ja) * 2011-03-28 2016-12-21 エスジェイティー モレキュラー リサーチ，エス．エル． メタボリック症候群の処置のための化合物
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4925099A (en) * 1998-08-12 2000-03-06 Pfizer Products Inc. Tace inhibitors
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
MEP28108A (en) * 2000-03-15 2010-10-10 Sanofi Aventis Deutschland Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2001068648A1 (fr) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Beta-carbolines substituees ayant une activite inhibitrice de l'ikb-kinase
ATE363473T1 (de) * 2001-09-19 2007-06-15 Pharmacia Corp Substituierte pyrazoloverbindungen zur behandlung von entzündungen
US9248124B2 (en) * 2001-11-07 2016-02-02 Millennium Pharmaceuticals, Inc. Use of inhibitors of IκB kinase for the treatment of cancer
ATE406360T1 (de) * 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.

Also Published As

Publication number Publication date
NO20054598D0 (no) 2005-10-06
ZA200508198B (en) 2007-01-31
NO20054598L (no) 2005-10-27
JP2006522824A (ja) 2006-10-05
RS20050832A (sr) 2007-12-31
MXPA05010793A (es) 2005-12-05
MA27837A1 (fr) 2006-04-03
EA009121B1 (ru) 2007-10-26
ECSP056145A (es) 2006-04-19
BRPI0409263A (pt) 2006-03-28
KR20060006031A (ko) 2006-01-18
WO2004092167A8 (fr) 2006-01-05
CA2521300A1 (fr) 2004-10-28
TNSN05257A1 (en) 2007-07-10
AU2004230952A1 (en) 2004-10-28
EP1611134A1 (fr) 2006-01-04
CO5700746A2 (es) 2006-11-30
CN1802375A (zh) 2006-07-12
EA200501584A1 (ru) 2006-06-30
NI200500174A (es) 2006-04-17
OA13115A (en) 2006-11-10
US20040235839A1 (en) 2004-11-25
CR8042A (es) 2006-05-30
US20100093713A1 (en) 2010-04-15
WO2004092167A1 (fr) 2004-10-28
US7727985B2 (en) 2010-06-01

Similar Documents

Publication Publication Date Title
US20100093713A1 (en) Beta-carbolines useful for treating inflammatory disease
CA2649775C (fr) Pyridine[3,4-b]pyrazinones
CA2409743C (fr) Derives de pyrrolopyridinone substitues utiles en tant qu'inhibiteurs de la phosphodiesterase
EP3710443A1 (fr) Composés et procédés pour la dégradation ciblée de polypeptides de kinase 4 associés au récepteur de l'interleukine 1
US7951801B2 (en) Beta-carbolines useful for treating inflammatory disease
AU2017239481A1 (en) DNA-PK inhibitors
AU2014240388A1 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
CA2608672A1 (fr) Pyridine [3,4-b] pyrazinones
WO2006126081A2 (fr) Pyridine [2,3-b] pyrazinones
CN122010947A (zh) 腺苷A2a受体的拮抗剂
JP7464526B2 (ja) ４－ヒドロキシピペリジン誘導体およびユビキチン特異的プロテアーゼ１９（ｕｓｐ１９）の阻害剤としてのその使用
US20050245563A1 (en) Chk-1 inhibitors
WO2009067233A1 (fr) Bêta-carbolines et leurs utilisations

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100323

Year of fee payment: 7

OBST Application withdrawn